期刊文献+

超高效液相色谱-串联质谱法测定人血浆中卡巴他赛与血浆蛋白的结合率 被引量:1

Determination of human plasma protein binding rate of cabazitaxel by UPLCMS/MS
原文传递
导出
摘要 目的建立并应用超高效液相色谱-串联质谱法(UPLC-MS/MS)测定人血浆中卡巴他赛与血浆蛋白的结合率。方法以拉洛他赛为内标,样品经叔丁基甲醚液液萃取,采用ACQUITYBEHC,。色谱柱(50mm×2.1mm,1.7μm);流动相:2mmol·L^-1醋酸铵水溶液-乙腈;流速:0.2mL·min^-1;进样量:5μL;柱温:35℃;采用ESI正离子源,定量分析离子反应分别为m/z836.36→m/z555.26(卡巴他赛)和m/z832.25→m/z551.08(内标拉洛他赛)。结合平衡透析法,测定了卡巴他赛的人血浆蛋白结合率。结果卡巴他赛浓度在5~1000ng·mL^-1范围内线性关系良好,定量下限为5ng·mL^-1,日内和日间精密度均小于15.0%。提取回收率为70.0%。91.4%,基质效应为87.4%~100.9%,可用于卡巴他赛的血浆蛋白结合率研究。卡巴他赛在低、中、高三个浓度下的人血浆蛋白结合率为(87.8±4.0)%、(76.4±0.8)%和(73.5±6.4)%。结论本方法简单、快速、灵敏,能满足分析要求。卡巴他赛与人血浆蛋白结合率较高,与血浆蛋白结合能力在考察的浓度范围内无浓度依赖性。 AIM To establish a rapid and sensitive analytical method based on ultra performance liquid chromatography-tandem mass spectrometry (UPLC- MS/MS) for the determination of the human plasma protein binding rate of cabazitaxel. METHODS The equilibrium dialysis was utilized to imitate the binding process between cabazitaxel and plasma protein. Samples were extracted with methyl tert-butyl ether using larotaxel as internal standard. The analysis was conducted with a Cls column (50 mm × 2.1 mm, 1.7 μm) and the column temperature was kept at 35 ℃ with flow rate at 0.2 mL· min^-1. The mobile phase consisted of acetonitrile and 2 mmol·L^-1 ammonium acetate and aliquot of 5 μL was injected for the UPLC-MS/MS analysis. Detection was performed on a tandem mass spectrometry with electrospray ionization source in the positive ion mode. Multiple reactions monitoring mode was used to quantify m/z 836.36 → m/z 555.26 (cabazitaxel) and m/z 832.25 → m/z 551.08 (IS), respectively. RESULTS The standard curves were linear over the range 5 - 1 000 ng·mL^-1 for plasma and dialysis samples with lower limit of quantification was 5 ng·mL^-1. The intra- and inter- day precision was less than 15.0%. Recoveries and matrix effects were satisfactory for all the samples, with 70.0% - 91.4%, and 87.4% - 100.9%, respectively. The validated method was successfully applied to the determination of binding rate of cabazitaxel in human plasma. The human plasma protein binding rate of cabazitaxel at low, middle and high concentrations were (87.8 ± 4.0) %, (76.4 ± 0.8) % and (73.5 ± 6.4) % respectively. CONCLUSION The method is simple, fast, sensitive and satisfied for the requirements. The binding power of cabazitaxel to human plasma is high without concentration dependence.
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2014年第5期379-383,共5页 Chinese Journal of New Drugs and Clinical Remedies
关键词 卡巴他赛 蛋白质结合 色谱法 高压液相 串联质谱法 cabazitaxel protein binding chromatography, high performance liquid tandem mass spectrometry
  • 相关文献

参考文献7

二级参考文献109

  • 1刘晓,陈晓辉,刘文涛,张加,毕开顺.阿比朵尔人血浆蛋白结合率的测定[J].中国新药与临床杂志,2007,26(2):115-119. 被引量:22
  • 2杨宣斌 熊方武.格列美脲治疗Ⅱ型糖尿病[J].国外医药·合成药、生化药、制剂分册,1997,18(1):61-61.
  • 3JEMAL A, SIEGEL R, WARD E, et al. Cancer statistics, 2009 [J]. CA Cancer JClin, 2009, 59(4): 225 -249.
  • 4PETRYLAK DP, TANGEN CM, HUSSAIN MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer [ J ]. N Engl J Med, 2004, 351(15) : 1513 -1520.
  • 5BERRY DL, MOINPOUR CM, JIANG CS, et al. Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone[ J]. J Clin Oncol, 2006, 24(18) : 2828 -2835.
  • 6Jevtana [ EB/OL ].[ 2010 - 11 - 02 ]. http ://www. accessdata. fda. gov/drugsatfda_docs/label/2010/2010231bl, pdf.
  • 7Sanofi-aventis. XRP6258 investigator's brochure[ M]. Antony (France) : Sanofi-aventis,2000.
  • 8ATTARD G, GREYSTOKE A, KAYE S, et al. Update on tubulin binding agents [ J ]. Pathol Biol( Paris), 2006, 54 ( 2 ) : 72 - 84.
  • 9PIVOTI X, KORALEWSKI P, HIDALGO JL, et al. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients [J]. Ann Oncol, 2008, 19(9) : 1547 -1552.
  • 10SEBASTIAN J, OUDARD S, OZGUROGLU M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic astration-resistant prostate cancer progressing after ocetaxel treatment: a randomised open-label trial [ J ]. Lancet, 2010, 376 ( 9747 ) : 1147 - 1154.

共引文献84

同被引文献3

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部